Living Cells – PharmaLive

FDA approves first biosimilar to Roche cancer drug Rituxan

Approvals, Biosimilars, Brain Infections, Cancer, Cells, FDA, FDA/Regulatory, Liver Damage, Living Cells, Non-Hodgkin Lymphoma, Shares

Celltrion Inc.’s Truxima became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.

November 28, 2018/by Reuters Health